Biotech News

Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors

Aptevo Therapeutics (APVO)Aptevo TherapeuticsFinancing

In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering potential for difficult-to-treat solid tumorsPreclinical work also showed that APVO711 both activated immune cells and blocked a signal that weakens their response -

Related news

APVOAptevo Therapeutics2026-10-14 12:46 EST

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

IRONDisc Medicine2026-10-21 00:52 EST

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

IRONDisc Medicine2026-10-19 20:01 EST

Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

APVOAptevo Therapeutics2026-10-26 12:05 EST

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

LYELLyell Immunopharma2026-11-04 14:02 EST

Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission

IDYAIDEAYA Biosciences2026-11-15 20:00 EST

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

IMTXImmatics2026-10-24 06:30 EST

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

BMYBMYBristol-Myers Squibb Company2026-11-18 14:10 EST

Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease

GSKGSK plc2026-10-23 23:00 EST

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

BMYBMYBristol-Myers Squibb Company2026-10-23 14:30 EST

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026

Aptevo Therapeutics

Multispecific Immunotherapy Platforms Aptevo Therapeutics is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer. Its ADAPTIR and ADAPTIR-FLEX platforms are designed to create molecules that engage multiple immune and tumor targets within a single therapeutic construct. Mipletamig Mipletamig is a...

Recent company news

Stock data

Close
0.41 USD
Market cap
6.28M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States